Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

August 1 Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals Inc.

EGRX

August 1 Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming August 1, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the “Class”) of investors who purchased Eagle Pharmaceuticals Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) securities between February 23, 2016 and March 18, 2016, inclusive (the “Class Period”). Eagle investors have until August 1, 2016 to file a lead plaintiff motion.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies, including misrepresentations about the FDA approval process for its new anticoagulant drug, KANGIO™.

On February 25, 2016, responding to inquiries about the pending New Drug Application (“NDA”) for the Company's anticoagulant drug KANGIO, Eagle’s CEO stated “we have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2.”

However, on March 18, 2016, Eagle disclosed that the FDA did not approve the NDA because it needed “additional information” regarding the substances used in KANGIO.

On this news, Eagle stock fell nearly 19% to close at just $43.50 per share on March 18, 2016.

If you purchased Eagle shares, you may move the Court no later than August 1, 2016 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com